{'fraction_non_alphanumeric': 0.05113636363636364, 'fraction_numerical': 0.009943181818181818, 'mean_word_length': 5.238938053097345, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Patients with non-Jo-1 anti-RNA-synthetase autoantibodies have worse survival than Jo-1 positive patients

We read with interest the manuscript by Aggarwal et al 1 entitled ‘ Patients with non-Jo-1 anti-RNA-synthetase autoantibodies have worse survival than Jo-1 positive patients ’. This large cohort study provides important information on outcomes for patients with antisynthetase syndrome (ASS), based on the specificity of the anti-RNA-synthetase autoantibody subtypes. Interestingly, the authors decided to include patients with anti-glycyl (EJ), anti-isoleucyl (OJ) and anti-asparagyl (KS)-tRNA-synthetase autoantibodies, something which had not yet been done in the previous studies,2 ,3 due to …